BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 21531450)

  • 1. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the opioid growth factor: opioid growth factor receptor axis for treatment of human ovarian cancer.
    Zagon IS; Donahue R; McLaughlin PJ
    Exp Biol Med (Maywood); 2013 May; 238(5):579-87. PubMed ID: 23856908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Jul; 236(7):883-95. PubMed ID: 21685240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The opioid growth factor-opioid growth factor receptor axis: homeostatic regulator of cell proliferation and its implications for health and disease.
    McLaughlin PJ; Zagon IS
    Biochem Pharmacol; 2012 Sep; 84(6):746-55. PubMed ID: 22687282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.
    Rahn KA; McLaughlin PJ; Zagon IS
    Brain Res; 2011 Mar; 1381():243-53. PubMed ID: 21256121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opioid growth factor receptor is unaltered with the progression of human pancreatic and colon cancers.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2006 Aug; 29(2):489-94. PubMed ID: 16820893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the opioid growth factor-opioid growth factor receptor axis in human ovarian cancer.
    Fanning J; Hossler CA; Kesterson JP; Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2012 Feb; 124(2):319-24. PubMed ID: 22037317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reepithelialization of the human cornea is regulated by endogenous opioids.
    Zagon IS; Sassani JW; McLaughlin PJ
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective blockade of the OGF-OGFr pathway by naltrexone accelerates fibroblast proliferation and wound healing.
    Immonen JA; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2014 Oct; 239(10):1300-9. PubMed ID: 25030485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Under-expression of the opioid growth factor receptor promotes progression of human ovarian cancer.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2012 Feb; 237(2):167-77. PubMed ID: 22328595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.
    Ludwig MD; Zagon IS; McLaughlin PJ
    Exp Biol Med (Maywood); 2018 Feb; 243(4):361-369. PubMed ID: 29307283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression of squamous cell carcinoma of the head and neck is associated with down-regulation of the opioid growth factor receptor.
    McLaughlin PJ; Zagon IS
    Int J Oncol; 2006 Jun; 28(6):1577-83. PubMed ID: 16685459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
    Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
    J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.